Apricus Biosciences
San Diego, California, United States
About Apricus Biosciences
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED. Vitaros® is approved in Europe and Canada and will be commercialized by Apricus’ marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox®, the Company’s product candidate for the treatment of FSAID, has successfully completed a nearly 400-subject proof-of-concept study.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $12.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2016)
- Ticker: nasdaq:APRI
- Website: apricusbio.com
- Phone: +1 858-222-8041
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/apricus-biosciences-2242009 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.